P
ProHub
English 简体中文 繁體中文
Hard Growth Strategy Profitability

Fringe Science

#Healthcare
ProHub Comment

This is a complex multi-stage pharmaceutical strategy case requiring candidates to synthesize market sizing, competitive positioning, clinical trial economics, and pricing strategy. The case tests both quantitative rigor (profit calculations across different scenarios) and qualitative judgment (market share assumptions based on clinical profiles and competitive dynamics).

Estimated Time 36 minutes
Difficulty Hard
Source Duke
20 / 100
Massive Dynamic is a multi-national pharmaceutical company. One of their assets, Cortexiphan, is an anti-infective that successfully treats three major types of hospital-born illness and is currently in Phase II clinical trials. Unfortunately, Massive Dynamic only has the capital to finance a Phase III clinical trial for one of the three illnesses with Cortexiphan treats. Walter Bishop, Chief Medical Officer of Massive Dynamic, has enlisted your help to decide which of the three possible indications for cortexiphan they should pursue to maximize profits over a five year-period post-launch.

Clarifying Information

  1. Drug is only likely to be approved in the US at this time
  2. Drug will be sold directly to hospitals by Massive Dynamic; therefore, no need to consider distribution channel costs, etc.
  3. No need to calculate based on NPV, just do total over five years w/out discounting
  4. Provide Exhibit 1 when asked about market size and/or competition
  5. Provide Exhibit 2 when asked about development costs or clinical profile
  6. Provide Exhibit 3 after an initial indication selected and pricing prompt given
Mock Interview
Interviewer

Massive Dynamic is a multi-national pharmaceutical company. One of their assets, Cortexiphan, is an anti-infective that successfully treats three major types of hospital-born illness and is currently in Phase II clinical trials. Unfortunately, Massive Dynamic only has the capital to finance a Phase III clinical trial for one of the three illnesses with Cortexiphan treats. Walter Bishop, Chief Medical Officer of Massive Dynamic, has enlisted your help to decide which of the three possible indications for cortexiphan they should pursue to maximize profits over a five year-period post-launch.

You

Thanks. Before analyzing, I'd like to clarify a few key questions...

Interviewer

Good question. Let me provide some background information...

You

Based on this, I suggest analyzing from these dimensions...

AI Score
Structure Analysis Communication Business Sense Quantitative
Practicing...
Score coming soon
Practice this case with AI Mock Interview

Pharmaceutical company must choose which of three indications to pursue for Phase III trial of anti-infective drug. Through systematic analysis of market size, competition, clinical profile, development costs, and pricing strategy, the aspergillosis indication emerges as most profitable with premium pricing.

Key Insights:

  1. Market size alone is insufficient—candidiasis has largest market ($25B) but poor clinical profile limits market share potential to 10%
  2. Expected profit framework must account for trial success probability: aspergillosis ($4.75B expected) outperforms despite higher development cost ($2B) due to 50% success rate and superior clinical positioning
  3. Premium pricing ($15/dose) generates higher profit ($28B) than parity ($9B) despite lower overall market share (50% vs 60%), demonstrating revenue per unit importance in pharmaceutical economics
  4. Formulary status acts as key intermediary variable linking price to market access and ultimate market share realization